Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Πέμπτη 21 Οκτ 2021
Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has a dismal prognosis. Ιt was found that T cells of patients relapsing with AML after allo-HCT exhibited reduced glycolysis and interferon-γ production. Functional studies in multiple mouse models of leukemia showed that leukemia-derived lactic...
Καταχωρήθηκε: Τρίτη 12 Οκτ 2021
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds...
Καταχωρήθηκε: Παρασκευή 08 Οκτ 2021
Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas
Καταχωρήθηκε: Παρασκευή 08 Οκτ 2021
A study using lithium for epithelial regeneration in acute GvHD was presented. Presenter:Dr Liga  Participants:Prof.Spyridonidis, Dr Tsokanas
Καταχωρήθηκε: Τρίτη 21 Σεπ 2021
Rates of CLABSI are the same in internal jugular vein-and subclavian vein-CVC after allogeneic HCTThe strongest risk factor for local inflammation or fever are >6 neutropenic CVC-days·Time to local inflammation is longer with CVC placed in the internal jugular vein·CVC placed in the subclavian...
Καταχωρήθηκε: Τρίτη 14 Σεπ 2021
Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO). Efficacy and safety of nivolumab in real-life for the treatment of R/R Hodgkin lymphoma is comparable with that reported in clinical trials.·The main reasons for nivolumab discontinuation were referral for transplantation and disease...
Καταχωρήθηκε: Παρασκευή 10 Σεπ 2021
In a cohort of 126 allogeneic HCT recipients transplanted 1-39 years ago,62% were seropositive/seroprotected for measles before any vaccination since transplantation. The seropositivity/seroprotection was associated with myeloproliferative disorder, reduced intensity or non-myeloablative conditioning and absence of acute grade>2 graft-versus-host disease.·Our findings strongly support a systematic assessment...
Καταχωρήθηκε: Τετάρτη 08 Σεπ 2021
Presenter: Dr Liga, Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τρίτη 31 Αύγ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τετάρτη 25 Αύγ 2021
A review on a very common complication in our patients. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Πέμπτη 19 Αύγ 2021
Which aml sr pts benefit from transplant. Another role of mrd. https://pubmed.ncbi.nlm.nih.gov/29601212/?dopt=Abstract Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τετάρτη 18 Αύγ 2021
https://pubmed.ncbi.nlm.nih.gov/33897681/ Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τετάρτη 04 Αύγ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Δευτέρα 02 Αύγ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τετάρτη 28 Ιούλ 2021
https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020010543/476241/CAR-HEMATOTOX-A-model-for-CAR-T-cell-related?redirectedFrom=fulltext Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τετάρτη 14 Ιούλ 2021
With a limited follow-up, the German experience (203 pts) with SOC CAR-T cells in LBCL is in keeping with the approval trials in terms of safety, whereas our efficacy data appear to be inferior to published results. ABSTRACT EBMT AA2-2 STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B-CELL LYMPHOMA: REAL WORLD...
Καταχωρήθηκε: Πέμπτη 08 Ιούλ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Δευτέρα 05 Ιούλ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali
Καταχωρήθηκε: Τετάρτη 30 Ιούν 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Τετάρτη 23 Ιούν 2021
Presenter: Dr Liga Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka
Βρέθηκαν 309 αποτελέσματα. Σελίδα 1 από 16
Σελίδα [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2021 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας